Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022–2023 Winter Season

Vaccination against COVID-19 and influenza provides the best defense against morbidity and mortality. Administering both vaccines concurrently may increase vaccination rates and reduce the burden on the healthcare system. This study evaluated the immunogenicity of healthcare workers in Israel who we...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 11; no. 10; p. 1624
Main Authors Moss, Stephen, Jurkowicz, Menucha, Nemet, Ital, Atari, Nofar, Kliker, Limor, Abd-Elkader, Bayan, Gonen, Tal, Martin, Emily Toth, Lustig, Yaniv, Regev-Yochay, Gili, Mandelboim, Michal
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.10.2023
MDPI
Subjects
Antibodies
Brief Report
Clinical trials
COVID-19
COVID-19 vaccines
Dosage and administration
Evaluation
Health aspects
Health care
hemagglutination
Hemagglutination inhibition
Immunization
Immunogenicity
Influenza
Influenza vaccines
Medical personnel
Morbidity
neutralization
Omicron
Public health
Seasons
Severe acute respiratory syndrome coronavirus 2
Vaccines
Winter
Israel
Thailand
Phuket Thailand
Online AccessGet full text

Cover

More Information
Summary:Vaccination against COVID-19 and influenza provides the best defense against morbidity and mortality. Administering both vaccines concurrently may increase vaccination rates and reduce the burden on the healthcare system. This study evaluated the immunogenicity of healthcare workers in Israel who were co-administered with the Omicron BA.4/BA.5 bivalent COVID-19 vaccine and the 2022–2023 quadrivalent influenza vaccine. SARS-CoV-2 neutralizing antibody titers were measured via microneutralization while influenza antibody titers were measured via hemagglutination inhibition. No immunogenic interference was observed by either vaccine when co-administered. Antibody titers against SARS-CoV-2 variants increased significantly in the cohort receiving the COVID-19 vaccine alone and in combination with the influenza vaccine. Antibody titers against the A/H1N1 influenza strain increased significantly in the cohort receiving the influenza vaccine alone and in combination with the COVID-19 vaccine. Antibody titers against B/Victoria increased significantly in the cohort that received both vaccines. This study has important public health implications for the 2023–2024 winter season, and supports co-administration of both vaccines as a viable immunization strategy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines11101624